Document:

Exhibit 10.10

Confidential portions of this Agreement have been omitted and filed separately
with the Commission subject to a request for confidential treatment.

<PAGE>

[GRAPHIC OMITTED]

     TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER

     School of Medicine
     Departments of Surgery
                                http://www.ttuhsc.edu/pages/surgery/default.html
     3601 4th Street STOP 8312
     Lubbock, Texas 79430-8312
     (806) 743-2370
     (806) 743-2113 - Fax

Arthur P. Bollon, Ph.D.
Chairman & CEO
HemoBioTech, Inc.
2110 Research Row, Suite 457
Dallas, TX 75235
Tel: (469) 585-7613; Fax: (972) 620-9830; E-mail: arthurb@flash.net

Re: Phase 2 of the Texas Tech-HemoBioTech Joint Blood Substitute Project.

Date: December 13, 2004

Dear Dr. Bollon:
Texas Tech Administration Officials and I acknowledge the receipt of the funds
for Phase II of the Texas Tech-HemoBioTech Joint Research Project. This week the
account will be established and after a few days actual work on the project will
begin.

We would like to thank you for hosting HemoBioTech's Board of Directors Meeting
at Texas Tech. We are pleased with the results of this important meeting. We are
glad that Mr. Baron, a new member of the Board of Directors, was pleased with
the scientific and technical capability of the Texas Tech Blood Substitute R&D
Team. We are confident that other members of your Board of Directors, Drs.
Mittemeyer and Haeussler will ensure the success of the project.

As we discussed earlier I am including new FDA Guidance for the Blood Substitute
Industry: "Criteria for Safety and Efficacy Evaluation of Oxygen Therapeutics as
Red Blood Cell Substitutes" which will supercede the 1990 "Points to Consider on
the Safety Evaluation of Hb-Based Oxygen Carriers" and replaces the 1997 draft
"Guidance for Industry: Efficacy Evaluation of Hb- and Perfluorocarbon-Based
Oxygen carriers." We can confer this document on Wednesday.

Dr. Bollon we are certain that under your leadership the blood substitute
project will be a commercial success.

Regards,

Jan

/s/ Dr. Jan Simoni
-----------------------------------------------
Dr. Jan Simoni
P.I. of Sponsored Research Agreement
Associate Research Professor of Surgery and Internal Medicine
Texas Tech University Health Sciences Center
Lubbock, TX 79430
Tel: 806-743-2460 ext. 246
Fax: 806-743-2113

Cc:

Dr. Barbara C. Pence, Professor and Associate VP for Research and Dean of the
Graduate School, TTUHSC, Lubbock, TX 79430

Dr. Bernard T. Mittemeyer, Professor and HemoBioTech's Board of Directors
Member, TTUHSC, Lubbock, TX 79430

Ms. June Howard, Director, Office of Sponsored Programs, TTUHSC, Lubbock, TX
79430

Dr. K. Lance Anderson, Director, Office of Technology Transfer and Intellectual
Properties, TTU & TTUHSC, Lubbock, TX 79409

<PAGE>

PROJECT TITLE:    TEXAS TECH-HEMOBIOTECH JOINT BLOOD  SUBSTITUTE PROJECT.
                  PHASE II: U.S. PATENT EXTENSION AND INITIAL IND STAGE.

PROJECT DIRECTOR (AT HEMOBIOTECH, INC.):
`                 Arthur P. Bollon, PhD, Chairman & CEO
                  HemoBioTech, Inc.
                  2110 Research Row, Suite 457, Dallas, TX 75235
                  Tel: 469-585-7613; Fax: 971-620-9830
                  Email: arthurb@flash.net
                  Web: http://www.hemobiotech.com

PROJECT PRINCIPAL INVESTIGATOR (AT TTUHSC):
                  Jan Simoni, DVM, PhD
                  Co-Inventor of Texas Tech Blood Substitute
                  Associate Research Professor of Surgery and Internal Medicine
                  Texas Tech University Health Sciences Center
                  School of Medicine
                  3601 4th Street, Office 3A119A, Lubbock, TX 79430
                  Tel: 806-743-2460 x 246; Fax: 806-743-2113
                  Email: jan.simoni@ttuhsc.edu

DATES OF THE ENTIRE PROPOSED PERIOD:
                  December 1, 2004 - November 30, 2005

TOTAL DIRECT COST REQUESTED FOR THE PROJECT:
                  $230,503

PERFORMANCE SITES: Department of Surgery
                   Texas Tech University Health Sciences Center
                   3601 4th Street, Lubbock, TX 79430, and
                   Texas Tech New Deal Farm
                   East of New Deal, TX 79405

APPLICANT ORGANIZATION:
                   Texas Tech University Health Sciences Center
                   Lubbock, TX 79430

TYPE OF ORGANIZATION:  State
ORGANIZATIONAL COMPONENT TO RECEIVE CREDIT FOR GRANT:
                   School of Medicine
OFFICIAL SIGNING FOR APPLICANT ORGANIZATION:
                   Barbara C. Pence, PhD, Assoc. Dean/Assoc. VP
                   Office of Research and Graduate School
                   Texas Tech University Health Sciences Center
                   3601 4th Street, BA 112; Lubbock, TX 79430
                   Tel: 806-743-2556; Fax: 806-742-2656
                   Email: barbara.pence@ttuhsc.edu
                   Signature: /s/ Barbara C. Pence     Date: 11/19/04

OFFICIAL IN BUSINESS OFFICE TO BE NOTIFIED ABOUT THIS FUNDING:
                   June Howard, Director
                   Office of Sponsored Program, TTUHSC
                   3601 4th Street, Office 1C283, Lubbock, TX 79430
                   Tel: 806-743-2960; Fax: 806-743-2656
                   Signature: /s/ June Howard          Date: 11/19/04

PRINCIPAL INVESTIGATOR SIGNATURE:                      DATE: 11/18/04

<PAGE>

                          Texas Tech-HemoBioTech Joint Blood Substitute Project.
                           Phase II: U.S. Patent Extension and Initial IND Stage
                                                                          Page 2

1. PROJECT DESCRIPTION:
The proposed project represents a joint effort between Texas Tech University
Health Sciences Center (TTUHSC) and HemoBioTech, Inc. with an objective to
commercialize the Texas Tech developed blood substitute product. The legal basis
for such an activity is the Sponsored Research Agreement and License Agreement
between Texas Tech University Health Sciences Center (a licensor) and
HemoBioTech, Inc (a licensee).

After active participation in Phase I of the project including:

     o   creation of a company structure;

     o   development of the business plan; and

     o   intellectual/scientific/technical support during the process of
         searching for an initial venture capital,

the Texas Tech Blood Substitute R&D team led by Dr. Simoni, was asked to provide
further assistance to the company. As requested by Dr. Arthur P. Bollon,
Chairman & CEO of HemoBioTech, Inc., during the October 28 meeting, new services
provided by Texas Tech to the company will include:

     o   completion and submission to the U.S. Patent and Trademark Office a
         new patent on the method for stimulating erythropoiesis with the Texas
         Tech developed blood substitute (Project I),

     o   transfer of the CMC, pre-clinical and clinical research data into
         digital pdf format (Project II),

     o   analysis and summarization of the CMC, pre-clinical and clinical
         research data for IND application (Project III),

     o   renovation and sanitation of the Texas Tech Blood Substitute Production
         Facility (Project IV), and

     o   establishment of the animal blood donor facility (Project V).

Each project will be done at Texas Tech University using the Texas Tech
intellectual and technical resources and be paid in advance by HemoBioTech, Inc.

PROJECT I: *

* The information omitted is confidential and has been filed separately with the
  Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.

<PAGE>

                          Texas Tech-HemoBioTech Joint Blood Substitute Project.
                           Phase II: U.S. Patent Extension and Initial IND Stage
                                                                          Page 3

*

To speed up the process, HemoBioTech, Inc. has agreed to provide the financial
resources to complete this study.

As requested by Dr. Bollon, this study should be completed in * after receiving
the necessary funds. This project will also require that Dr. Simoni will
prepare, in the *, a complete patent application.

*

The detailed budget is presented as ATTACHMENT 1.

PROJECT II: The transfer of the CMC, pre-clinical and clinical data into a pdf
file will require manual handling of ca. * different documents. This work will
be done by the Electron Microscopy and Medical Photography Center of TTUHSC. The
entire process will be coordinated by Dr. Simoni, and is required by the FDA.

The detailed budget and timetable of completion is presented as ATTACHMENT 2.

PROJECT III: Analysis and summarization of the *, pre-clinical and clinical
research data will require evaluation of ca. * different documents. This work
will be done by Dr. Simoni * and Dr. Mario Feola, an employee of HemoBioTech,
Inc. (pre-clinical and clinical data). This project (Dr. Simoni's part) will be
completed in * days after completion of the EPO study. Dr. Feola's part will be
completed in

The detailed budget is presented in ATTACHMENT 1.

* The information omitted is confidential and has been filed separately with the
  Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.

<PAGE>

                          Texas Tech-HemoBioTech Joint Blood Substitute Project.
                           Phase II: U.S. Patent Extension and Initial IND Stage
                                                                          Page 4

PROJECT IV: The remodeling and sanitation of the Blood Substitute Production
Facility will be done by the Texas Tech's Facilities Planning and Construction
Department and the Blood Substitute's R&D Team under the direction of Dr.
Simoni. This project can be completed in 60 days after receiving the necessary
funds.

The detailed budget is presented as ATTACHMENT 3.

PROJECT V: The establishment of the animal blood donor facility will be done in
cooperation with the Department of Animal Sciences at TTU. This facility will be
located at * in New Deal and supervised by Dr. Simoni. The remodeling/renovation
part of this project can be completed in * days after receiving the necessary
funds. This project will continue through the entire funding period.

The detailed budget and timetable of completion is presented as ATTACHMENT 4.

2. TECHNICAL AND MANAGERIAL RESOURCES. Texas Tech University Health Sciences
Center with twenty years of experience in the blood substitute field has all
intellectual and technical resources to successfully complete Phase II of the
project.

All the personnel involved are highly qualified, well recognized experts in the
blood substitute field. The proposed structure for the management team was
presented to Dr. Bollon during the October 28 meeting.

3. FUNDING REQUESTS: The total funds requested for Phase II (projects I, III, IV
and V) of the project are $230,502. This amount includes 25% overhead that will
cover use of the TTUHSC facilities during the funding period.

*

The detailed budget for each project is presented as attachments 1, 3 and 4.

The budget for Project 2 * is presented separately (SEE ATTACHMENT 2). The funds
for Project 2 * will be transferred directly from HemoBioTech, Inc. to EM Center
at TTUHSC *. Dr. Simoni and other members of his Blood Substitute R&D Team are
not HemoBioTech employees and should be reimbursed by the company for their
services. Moreover, Dr. Simoni does not own any HemoBioTech's stock.

* The information omitted is confidential and has been filed separately with the
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.

<PAGE>

PROJECT II

ATTACHMENT 1
PROJECT TITLE:        The Texas Tech-HemoBioTech Joint Blood Substitute Project.
                      Phase II: U.S. Patent Extension and Initial IND Stage.

<TABLE>
<CAPTION>
PROJECT DIRECTOR (at HemoBioTech, Inc.):                        Dr. Arthur P. Bollon
PROJECT PRINCIPAL INVESTIGATOR (at TTUHSC):                     Dr. Jan Simoni
DETAILED BUDGET FOR PHASE II OF THE PROJECT:

FROM: December 1, 2004                                          THROUGH: November 30, 2005/*
SALARY:
NAME                  ROLE ON         TYPE      %              DOLLAR AMOUNT REQUESTED
                      PROJECT         APPT      EFF    SALARY    SALARY      FRINGE    TOTAL
                                      (mo)               BASE   REQUESTED
<S>                   <C>             <C>       <C>     <C>     <C>          <C>       <C>

SOMONI, Jan           P.I.            12         *        *         *          *         *
MOELLER, John F.      Post-doc        12         *        *         *          *         *
SIMONI, Grace         Med. Res.       12         *        *         *          *         *
To be hired           Animal Tech.    12         *        *         *          *         *
SALARY SUBTOTALS:
CONSULTANTS
EQUIPMENT (Itemize):
Phase II of this project will not require any equipment above $*.
However, modern computer (laptop) is needed for data collection and acquisition:         *
SUPPLIES: (Itemize by category):                                                         *
*
ALTERATIONS AND RENOVATIONS:
Renovation and sanitation the Texas Tech Blood Substitute Production Facility:           *
(the exact cost will be determined later)
Renovation/remodeling of the Animal Blood Donor Facility (New Deal Farm):                *
(Cattle Facility Option 2)
OTHER EXPENSES:                                                                          *
Photocopying, postage, phone, secretarial, e-mail/internet connection:                   *
(Cost of the CMC, pre-clinical, clinical research data transfer into the pdf
file presented separately as Attachment 2)                                               *
TRAVEL: For P.I. and co-investigators to travel to company headquarter,
FDA, etc.:                                                                               *
SUBTOTAL DIRECT COST FOR PHASE II OF THE PROJECT:                                        *
TTUHSC OVERHEAD (25% of 158,002 base-excluding alterations/renovations)
TOTAL FOR PHASE II:                                                                  230,503
</TABLE>

*

* The information omitted is confidential and has been filed separately with the
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.

<PAGE>

                          Texas Tech-HemoBioTech Joint Blood Substitute Project.
                           Phase II: U.S. Patent Extension and Initial IND Stage
                                                                          Page 5

Since Dr. Simoni and his team members will provide services to the company on a
regular basis, therefore the salaries for the personnel are for 12 months. After
completion of the proposed Phase II of the project the personnel will be
assigned to the next phase of the program.

Dr. Mario Feola, however, as a full time HemoBioTech's employee and no longer
employed by the Texas Tech University System, should not be reimbursed for his
services through this Sponsored Research Agreement.

SUBMITTED BY:
JAN SIMONI, DVM, PHD
Associate Research Professor of Surgery and Internal Medicine
P.I. of Sponsored Research Agreement
TTUHSC, School of Medicine
Lubbock, TX 79430
SIGNATURE: /s/ Jan Simoni                                         DATE: 11/18/04

APPROVED BY:
BARBARA C. PENCE, PH.D.
Associate Vice President for Research and
Associate Dean for Research and the Graduate School
Office of Research and the Graduate School, TTUHSC, Lubbock, TX 79430
SIGNATURE: /s/ Barbara C. Pence                                   DATE: 11/19/04

MS. JUNE HOWARD
Director, Office of Sponsored Programs
TTUHSC, Lubbock, TX 79430
SIGNATURE: /s/ June Howard                                        DATE: 11/19/04

LANCE ANDERSON, JD
Director, Office of Technology Transfer and Intellectual Properties
TTU & TTUHSC, Lubbock, TX 79414
SIGNATURE: /s/ Lance Anderson                                     DATE: 11/19/04

<PAGE>

PROJECT II

ATTACHMENT 2

DOCUMENT SCANNING AND CONVERSION TO PDF

BASED ON AN ANTICIPATED VOLUME OF * PAGES:

The department of Medical Photography and Electron Microscopy will scan and
convert documents of PDF at the rate of * to * per page (* to *). Rate applied
will be based on the complexity of scanning and converting individual documents.
We do not believe that actual cost will be the maximum figure due to the fact
that a large majority of the documents will not be highly complex. However, the
final cost will be established after the project has been completed.

As we discussed during the meeting, Oct 28, 2004; Medical Photography can
provide other services relating to the presentation of IND research data as
required by the FDA. Our unit can also help in the preparation of clinical and
research data during phase one of clinical trial. Such activities will require
the development of a supplemental budget. We are open to other request relating
to electronic documentation, presentation and secure transfer of data generated
through activities at Texas Tech University Health Sciences Center Sponsored
Research Agreement or directly to HemoBio Tech Inc.

DOCUMENT SCANNING/CONVERSION TIMETABLE:

Medical Photography and Electron Microscopy estimates it will take approximately
* days to properly scan and convert the anticipated volume, * pages. All
documents will be prepared according to Guidance for Industry Providing
Regulatory Submission is Electronic Format -- General Considerations, U.S.
Department of Health and Human Services Food and Drug Administration.

ADDENDUM: BID ACCEPTANCE, NOVEMBER 18, 2004
IN REFERENCE TO THE HEMOBIO TECH LETTER SENT TO DR. JAN SIMONI, DATED
NOVEMBER 6, 2004.
The department of Medical Photography and Electron Microscopy will perform the
transfer of CMC information to a digital format at the rate of * to * per page,
not to exceed * to * for documents required to complete Phase II. Work will
begin only after billing and payment procedures have been established between
the department of Medical Photography and Electron Microscopy and HemoBio Tech.
To set up these procedures, please contact:

Neal Hinkle
Manager -- Medical Photography and Electron Microscopy
Texas Tech University Health Sciences Center
3601 4th Street STOP 9042
Lubbock, Texas 79430-9042

(806) 743-1366 Office
(806) 743-1221 FAX

neal.hinkle@ttuhsc.edu

* The information omitted is confidential and has been filed separately with the
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.

<PAGE>

PROJECT II
ATTACHMENT 3

RENOVATION AND SANITATION OF THE TEXAS TECH BLOOD SUBSTITUTE
PRODUCTION FACILITY.

The cost should not exceed *.

The renovation and sanitation of the Texas Blood Substitute Production facility
will include:

*

*

* The information omitted is confidential and has been filed separately with the
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.Exhibit 10.11

Confidential portions of this Agreement have been omitted and filed separately
with the Commission subject to a request for confidential treatment.

<PAGE>

                               License Agreement
                          Texas Tech University System

This Agreement is made and entered into this 22nd day of January, 2002 (the
"Effective Date"), by and between Texas Tech University System, an institution
of higher education having its place of business at Box 42007, Lubbock, Texas
79409-2007 (hereinafter referred to as "LICENSOR"), and HemoBioTech, Inc., a
corporation duly organized under the laws of the State of Texas and having its
principal office at Suite 2006, 15889 Preston Road, Dallas, Texas 75248
(hereinafter referred to as "LICENSEE").

                                   WITNESSETH
                                   ----------

       WHEREAS, LICENSOR is the owner of certain PATENT RIGHTS (as later defined
herein) relating to LICENSOR Case No. TTU D-0177, "Blood Substitute" by Drs.
Mario Feola, Jan S. Simoni, and Peter C. Canizaro, and has the right to grant
licenses under said PATENT RIGHTS, subject only to a possible royalty-free,
nonexclusive license heretofore granted to the United States Government;

       WHEREAS, LICENSOR desires to have the PATENT RIGHTS developed and
commercialized to benefit the public and is willing to grant a license
thereunder;

       WHEREAS, LICENSEE has represented to LICENSOR, to induce LICENSOR to
enter into this Agreement, that LICENSEE has represented that it will cause the
formation of a start-up company which shall commit itself to a thorough,
vigorous, and diligent program of exploiting the PATENT RIGHTS so that public
utilization shall result therefrom; and

       WHEREAS, LICENSEE desires to obtain a license under the PATENT RIGHTS
upon the terms and condition hereinafter set forth;

       WHEREAS, LICENSEE acknowledges that if funds obtained from the U.S.
Government are co-mingled with funds obtained from LICENSEE in support of
sponsored research under any future sponsored research agreements, then any
license granted would be subject to rights in the U.S. Government under 37 CFR
part 401, should they exist;

       NOW, THEREFORE, in consideration of the premises and the mutual covenants
contained herein, the parties hereto agree as follows:

                                       1
<PAGE>

                            ARTICLE 1 - DEFINITIONS

       For the purposes of this Agreement, the following words and phrases shall
have the following meanings:

       1.1    "LICENSEE" shall include HemoBioTech, Inc., and any subsequent
start-up company approved by LICENSOR.

       1.2    "PATENT RIGHTS" shall mean all of the following LICENSOR
intellectual property:

       (a) the United States and foreign patents and/or patent applications
       listed in Appendices A and B; and any patent application filed pursuant
       to the terms of this Agreement in the name of the LICENSOR and/or
       Biological Material arising out of a Designated Invention;

       (b) United States and foreign patents issued from the applications
       arising from (a) and from divisional and continuation of these
       applications;

       (c) Any reissues of United States patents described in (a or (b), above.

       1.3    A "LICENSED PRODUCT" shall mean any product or part thereof which:

       (a) is covered in whole or in part by an issued, unexpired claim or a
       pending claim contained in the PATENT RIGHTS in the country in which any
       such product or part thereof is made, used or sold; or

       (b) is manufactured by using a process or is employed to practice a
       process which is covered in whole or in part by an issued, unexpired
       claim or a pending claim contained in the PATENT RIGHTS in the country in
       which any LICENSED PROCESS is used or in which such product or part
       thereof is used or sold.

       1.4    A "LICENSED PROCESS" shall mean any process which is covered in
whole or in part by an issued, unexpired claim or a pending claim contained in
the PATENT RIGHTS.

       1.5    "NET SALES" shall mean LICENSEE's (and its sublicensees') billings
for LICENSED PRODUCTS and LICENSED PROCESSES produced hereunder less the sum of
the following:

                                       2
<PAGE>

       (a) discounts allowed in amounts customary in the trade;

       (b) sales, tariff duties and/or use taxes directly imposed and with
       reference to particular sales;

       (c) outbound transportation prepaid or allowed; and

       (d) amounts allowed or credited on returns.

       No deductions shall be made for commissions paid to individuals whether
they be with independent sales agencies or regularly employed by LICENSEE and on
its payroll, or for cost of collections. LICENSED PRODUCTS shall be considered
"sold" when billed out or invoiced.

       1.6    "LICENSE YEAR" shall mean each twelve (12) month period beginning
on the effective date of this Agreement first written above and thereafter on
the anniversary date thereof.

       1.7    DESIGNATED INVENTION shall mean any patentable invention or
proprietary Biological Material, in each case, created and/or conceived and/or
reduced to practice, by any employees of LICENSOR funded under a future
sponsored research agreement funded by LICENSEE and which LICENSEE, in a written
notice to LICENSOR within 90 days after LICENSEE first receives written
notification of such invention or Biological Material in accordance with the
terms of the sponsored research agreement, shall have designated as an invention
it wishes to license under the terms of this Agreement.

       1.8    BIOLOGICAL MATERIAL shall mean any protein, gene, gene vector,
plasmid or other construct, cell line, hybridoma, monoclonal antibody or other
similar biological materials, or derivatives or analogs thereof, created by
employees of the Texas Tech University System and arising out of the sponsored
research, which is or is subject to becoming a Designated Invention.

       1.9   TECHNICAL INFORMATION means and includes all technical
information, developments, discoveries, know-how, methods, techniques, formulae,
processes, and other information that are conceived and/or discovered and/or
reduced to practice during the course of the sponsored research. "Technical
Information" shall exclude any of the foregoing that are included in a claim of
the Licensed Patents, or Licensed Applications or that are Biological Materials.

                                       3
<PAGE>

                                ARTICLE 2--GRANT

       2.1    LICENSOR hereby grants to LICENSEE the exclusive right and license
to practice under the PATENT RIGHTS and, to the extent not prohibited by other
patents, to make, have made, use, lease, sell, and import LICENSED PRODUCTS and
to practice the LICENSED PROCESSES world-wide, until the end of the term for
which the patent rights are granted unless this Agreement shall be sooner
terminated according to the terms hereof.

       2.2    LICENSEE agrees that LICENSED PRODUCTS leased or sold in the
United States shall be manufactured substantially in the United States.

       2.3    LICENSOR reserves the right to practice under the PATENT RIGHTS
for its own noncommercial research purposes.

       2.4    LICENSEE may sublicense its license hereunder to any third party
provided that LICENSEE finds the sublicensee generally acceptable (such
acceptance is not to be unreasonably withheld), that all sublicensees shall be
obligated to all the terms and conditions of this Agreement protective of
LICENSOR and that LICENSEE shall make all reasonable efforts to ensure
compliance of the sub-licensee on all provisions of this Agreement that are
beneficial to or protective of the LICENSOR. LICENSEE has the right, to the
extent permitted by State and Federal law and to the extent that it pays for
such use, including overhead charges, to use its personnel, labs, facilities and
equipment in the production of LICENSED PRODUCTS until the end of phase two of
clinical testing unless this Agreement shall be sooner terminated according to
the terms hereof.

       2.5    LICENSOR recognizes that one of more of its employees may leave
LICENSOR to join LICENSEE full time and that LICENSOR will not prevent or hold
either employee or LICENSEE liable for such act. Furthermore, LICENSOR
recognizes that LICENSEE may ask select employees, directions and affiliates of
LICENSOR to act as advisors, directors and part-time associates and consultants
and that LICENSEE may compensate for such an act, in the form of cash and or
stock options.

       2.6    LICENSEE agrees to forward to LICENSOR a copy of any and all
sublicense agreements promptly upon execution by the parties.

       2.7    LICENSEE shall not receive from sublicensees anything of value in
lieu of cash payments in consideration for any sublicense under this Agreement,
without the express prior written permission of or sharing agreement with
LICENSOR.

                                       4
<PAGE>

       2.8    LICENSOR recognizes that LICENSEE may encounter patents held by
third parties which are superior to both LICENSOR's and LICENSEE's patents and
that a cross-license between LICENSEE and such third party may be necessary in
order to enable LICENSEE to exercise the license herein granted. In that event,
LICENSEE shall have the right to enter into cross-licensing agreements with
third parties and to grant cross-licenses under any and all of that PATENTS,
provided that such cross-license does not relieve LICENSEE from any obligation
hereunder.

       2.9    The license granted hereunder shall not be construed to confer any
rights upon LICENSEE by implication, estoppel or otherwise as to any technology
not specifically set forth in Appendices A and B hereof, or which is a
Designated Invention.

       2.10   Further, LICENSOR grants LICENSEE the exclusive right to use
Technical Information to the extent necessary or appropriate to make, use or
sell a Licensed Product, PROVIDED, HOWEVER, that the grant of such a right with
respect to the Technical Information shall not in any way affect the rights of
employees and researchers of LICENSOR to make publications and presentations are
made in compliance of any future sponsored research agreement.

       Notwithstanding anything in this Agreement, the employees and researchers
of LICENSOR may make Biological Materials available to other academic
researchers with an appropriate standard Biological Materials Agreement that
prevents further transfer of such Biological Materials and grants no commercial
rights, in order to satisfy the requirements of a journal publisher.

                            ARTICLE 3--DUE DILIGENCE

       3.1    LICENSEE shall use its best efforts to bring one of more LICENSED
PRODUCTS or LICENSED PROCESSES to market through a thorough, vigorous and
diligent program for exploitation of the PATENT RIGHTS and to continue active,
diligent marketing efforts for one or more LICENSED PRODUCTS or LICENSED
PROCESSES throughout the life of this Agreement.

       (a) LICENSEE shall deliver to LICENSOR on or before December 31st a
       business plan showing the amount of money, number and kind of personnel
       and time budgeted and planned for each phase of development of the
       LICENSED PRODUCTS and LICENSED PROCESSES and shall provide similar
       reports to LICENSOR on or before December 31st of each year.

                                       5
<PAGE>

                    ARTICLE 4--PAYMENTS MADE IN CONSIDERATION
                   OF THE EXECUTION OF THIS LICENSE AGREEMENT

       4.1    LICENSEE agrees to pay The Texas Tech System Research and Economic
Development Foundation (hereinafter referred to as "FOUNDATION") five percent
(5%) of the authorized founding stock in LICENSEE or its successors. This
payment is in exchange for royalties, licensing fees, sublicensing fees and any
and all other payments and considerations associated with this Agreement.
Throughout the initial phase of financing or capital acquisition, The
Foundation's five percent equity share shall be protected against dilution until
LICENSEE has expended fifteen million dollars ($15,000,000.00) in capital.
Thereafter, FOUNDATION's equity interest shall be dilutable.

In addition, LICENSEE agrees to create a special fund in the amount of $1.2
Million dollars dedicated over a period of four years to support efforts in
incubating and commercializing other LICENSOR technologies. LICENSEE reserves
the right of first refusal on licensing and commercializing other technologies
developed by LICENSOR.

                        ARTICLE 5--INTELLECTUAL PROPERTY
                        PROTECTION AND PAYMENT OF COSTS

       5.1    If future Designated Inventions come into existence, LICENSEE
agrees to pay all direct and documentable prosecution costs for such Designated
Inventions paid by LICENSOR at least through an appeal to the U.S. Patent and
Trademark Office Board of Appeals.

       5.2    Upon successful commercialization and where maintenance fees are
due on Patent Rights throughout the world and LICENSEE remains exclusively
licensed, LICENSEE agrees to reimburse LICENSOR for the costs of said
maintenance within thirty (30) days of Notice thereof to LICENSEE by LICENSOR.

       5.3    Should the opportunity to file foreign counterpart applications of
Designated Inventions exist, LICENSEE may designate foreign countries where
counterpart foreign applications shall be filed. Title to such foreign patent
applications shall be in LICENSOR. LICENSEE agrees to pay for all expenses
incurred in the preparation, filing, prosecution, renewal and continuation of
patents and patent applications in said designated countries including all
taxes, official fees and attorney's fees.

                                       6
<PAGE>

       5.4    LICENSEE may designate by notice to LICENSOR countries where
applications with respect to Designated Inventions shall be filed, which may
include the United States or any other country. Title to inventions made solely
by inventive contributions of employees of the LICENSOR shall be in LICENSOR;
title to inventions made solely by inventive contributions of employees of
LICENSEE shall be in LICENSEE; and title to inventions made by joint inventive
contributions of employees of both the LICENSOR AND LICENSEE shall be jointly
owned by the LICENSOR and LICENSEE. LICENSEE agrees to pay for all reasonable
and necessary out-of-pocket expenses incurred in the preparation, filing,
prosecution, maintenance, renewal and continuation of said patents and
applications in said designated countries, including all taxes, official fees
and attorney's fees. The patent law firm selected shall be mutually acceptable
to LICENSOR and LICENSEE. LICENSOR shall be the client in the attorney-client
relationship with such law firm and may provide instructions to such law firm
regarding the scope and content of applications to be filed and prosecuted,
subject to the right of LICENSEE to request LICENSOR to instruct such law firm
to cover any additional matters as LICENSEE may desire to assure that such
application covers all items of commercial interest and importance. LICENSOR
will honor such requests of LICENSEE. LICENSOR and LICENSEE each shall receive
copies of all correspondence with respect to such preparation, filing,
prosecution, renewal and continuation of Licensed Patents and Licensed
Applications. LICENSOR AND LICENSEE shall consult with each other regarding all
such patent application matters and the costs associated therewith.
Notwithstanding the foregoing, LICENSEE may elect in writing to be released from
its license in any of the patents and applications in a particular country at
any time after initial filing costs have been paid, in which event it shall
thereafter, upon notice of such election being given to LICENSOR, have no
obligation to reimburse LICENSOR for any future expenses relating to such
patent, or application therefore in such country.

                         ARTICLE 6--REPORTS AND RECORDS

       6.1    LICENSEE shall keep full, true and accurate books of account
containing all particulars that may be necessary for the purpose of showing the
amounts payable to LICENSOR hereunder. Said books of account shall be kept at
LICENSEE's principal place of business or the principal place of business of the
appropriate division of LICENSEE to which this Agreement relates. Said books and
the supporting data shall be open at all reasonable times for five (5) years
following the end of the license year to which they pertain, to the inspection
of LICENSOR or its agents for the purpose of verifying LICENSEE's royalty
statement or compliance in other respects with this Agreement. Should such
inspection lead to the discovery of a greater than ten percent (10%) discrepancy
in re-

                                       7
<PAGE>

porting to LICENSOR's detriment, LICENSEE agrees to pay the full cost of such
inspection.

       6.2    Before the first commercial sales of a LICENSED PRODUCT or
LICENSED PROCESS, LICENSEE shall submit the reports due under Paragraph 3.1(a)
on December 31st of each year. After the first commercial sales of a LICENSED
PRODUCT or LICENSED PROCESS, LICENSEE, within sixty (60) days after March 31,
June 30, September 30 and December 31, of each license year, shall deliver to
LICENSOR true and accurate reports, giving such particulars of the business
conducted by LICENSEE and its sublicensees during the preceding three-month
period under this Agreement as shall be pertinent to a royalty accounting
hereunder. These shall include at least the following:

              (a)    number of LICENSED PRODUCTS manufactured and sold by
              LICENSEE and all sublicensees; and if multiple patents or patent
              applications are contained in Patent rights, which of the patents
              or patent applications apply to each LICENSED PRODUCT;

              (b)    total billings for LICENSED PRODUCTS sold by LICENSEE and
              all sublicensees; each distinct product or model number separately
              accounted for

              (c)    accounting for all LICENSED PROCESSES used or sold by
              LICENSEE and all sublicensees:

              (d)    deductions applicable as provided in Paragraph 1.5;

              (e)    names and addresses of all sublicensees of LICENSEE.

       6.3    On or before the ninetieth (90th) day following the close of
LICENSEE's fiscal year, LICENSEE shall provide LICENSOR with LICENSEE's
certified financial statements for the preceding fiscal year including, at a
minimum, a Balance Sheet and an Operating Statement.

                            ARTICLE 7 - INFRINGEMENT

       7.1    LICENSEE shall inform LICENSOR promptly in writing of any alleged
infringement of the PATENT RIGHTS by a third party and of any available evidence
thereof.

       7.2    During the term of this Agreement, LICENSOR shall have the right,
but shall not be obligated, to prosecute at its own expense all infringements of
the PATENT RIGHTS and, in furtherance of such right, LICENSEE hereby agrees

                                       8
<PAGE>

that LICENSOR may include LICENSEE as a party plaintiff in any such suit,
without expense to LICENSEE. The total cost of any such infringement action
commenced or defended solely by LICENSOR shall be borne by LICENSOR and LICENSOR
shall keep any recovery or damages for past infringement derived therefrom.

       7.3    If within six (6) months after having been notified of any alleged
infringement, LICENSOR shall have been unsuccessful in persuading the alleged
infringer to desist and shall not have brought and shall not be diligently
prosecuting an infringement action, or if LICENSOR shall notify LICENSEE at any
time prior thereto of its intention not to bring suit against any alleged
infringer, then, and in those events only, LICENSEE shall have the right, but
shall not be obligated, to prosecute at its own expense any infringement of the
PATENT RIGHTS, and LICENSEE may, for such purposes, use the name of LICENSOR as
party plaintiff; provided, however, that such right to bring such an
infringement action shall remain in effect only for so long as the license
granted herein remains exclusive. No settlement, consent judgment or other
voluntary final disposition of the suit may be entered into without the consent
of LICENSOR, which consent shall not unreasonably be withheld. LICENSEE shall
indemnify LICENSOR against any order for costs that may be made against LICENSOR
in such proceedings.

       7.4    In the event that a declaratory judgment action alleging
invalidity or noninfringement of any of the PATENT RIGHTS shall be brought
against LICENSEE, LICENSOR, at its option, shall have the right, within thirty
(30) days after commencement of such action, to intervene and take over the sole
defense of the action at its own expense.

       7.5    In any infringement suit as either party may institute to enforce
the PATENT RIGHTS pursuant to this Agreement, the other party hereto shall, at
the request and expense of the party initiating such suit, cooperate in all
respects and, to the extent possible, have its employees testify when requested
and make available relevant records, papers, information, samples, specimens,
and the like.

       7.6    LICENSEE, during the exclusive period of this Agreement, shall
have the sole right in accordance with the terms and conditions herein to
sublicense any alleged infringer for future use of the PATENT RIGHTS. Any
upfront fees as part of such a sublicense shall be shared equally between
LICENSEE and LICENSOR; other royalties shall be treated per Article 4.

                                       9
<PAGE>

                         ARTICLE 8 - PRODUCT LIABILITY

       8.1    LICENSEE shall at all times during the term of this Agreement and
thereafter, indemnify, defend and hold LICENSOR, its trustees, directors,
officers, employees and affiliates, harmless against all claims, proceedings,
demands and liabilities of any kind whatsoever, including legal expenses and
reasonable attorneys' fees, arising out of the death of or injury to any person
or persons or out of any damage to property, or resulting from the production,
manufacture, sale, use, lease, consumption or advertisement of the LICENSED
PRODUCT(s) and/or LICENSED PROCESS(es) or arising from any obligation of
LICENSEE hereunder, excepting only claims that the PATENT RIGHTS infringe third
party intellectual property.

       8.2    No other action on the part of LICENSOR is or will be necessary to
authorize the execution, delivery or performance of this Agreement. This
Agreement has been duly executed and delivered by LICENSOR, and this Agreement
constitutes the valid and legally binding obligation of LICENSOR, enforceable
against it according to its terms.

       8.3    Insofar as LICENSOR is aware, the execution and delivery of this
Agreement by LICENSOR and the performance of its obligations hereunder will not
conflict with or violate any of the terms, conditions or provisions of or
constitute a default under any contract, instrument, agreement, law, order,
regulation, judgment or license to which LICENSOR is a party or may be bound.
LICENSOR represents and warrants that, to its present best knowledge and belief,
the PATENT RIGHTS and the LICENSED PRODUCT and/or LICENSED PROCESS(es) made,
used, sold, or otherwise disposed of under any license granted herein are or
will be free from liability, infringement of patents or property rights owned by
third parties.

       8.4*

----------
* The information omitted is confidential and has been filed separately with the
  commission pursuant to Rule 406 of the Securities Act of 1933, as amended.

                                       10
<PAGE>

*

       8.5    EXCEPT AS OTHERWISE EXPRESSLY SET FORTH IN THIS AGREEMENT,
LICENSOR, ITS TRUSTEES, DIRECTORS, OFFICERS, EMPLOYEES, AND AFFILIATES MAKE NO
REPRESENTATIONS AND EXTEND NO WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED,
INCLUDING BUT NOT LIMITED TO WARRANTIES OF MERCHANTABILITY, FITNESS FOR A
PARTICULAR PURPOSE, VALIDITY OF PATENT RIGHTS CLAIMS, ISSUED OR PENDING, AND THE
ABSENCE OF LATENT OR OTHER DEFECTS, WHETHER OR NOT DISCOVERABLE. NOTHING IN THIS
AGREEMENT SHALL BE CONSTRUED AS A REPRESENTATION MADE OR WARRANTY GIVEN BY
LICENSOR THAT THE PRACTICE BY LICENSEE OF THE LICENSE GRANTED HEREUNDER SHALL
NOT INFRINGE THE PATENT RIGHTS OF ANY THIRD PARTY. IN NO EVENT SHALL LICENSOR,
ITS TRUSTEES, DIRECTORS, OFFICERS, EMPLOYEES AND AFFILIATES BE LIABLE FOR
INCIDENTAL OR CONSEQUENTIAL DAMAGES OF ANY KIND, INCLUDING ECONOMIC DAMAGE OR
INJURY TO PROPERTY AND LOST PROFITS, REGARDLESS OF WHETHER LICENSOR SHALL BE
ADVISED, SHALL HAVE OTHER REASON TO KNOW, OR IN FACT SHALL KNOW OF THE
POSSIBILITY.

       8.6    EXCEPT AS OTHERWISE EXPRESSLY SET FORTH IN THIS AGREEMENT,
LICENSEE, ITS DIRECTORS, OFFICERS, EMPLOYEES AND AFFILIATES MAKE NO
REPRESENTATIONS AND EXTEND NO GUARANTEES OF ANY KIND, EITHER EXPRESS OR IMPLIED,
INCLUDING BUT NOT LIMITED TO WARRANTIES AND OR GUARANTEES OF CLINICAL TESTING,
COMMUNICABILITY AND MERCHANTABILITY OF PATENT RIGHTS. IN NO EVENT SHALL
LICENSEE, ITS DIRECTORS, OFFICERS, EMPLOYEES AND AFFILIATES BE LIABLE FOR
INCIDENTAL OR CONSEQUENTIAL DAMAGES OF ANY KIND, INCLUDING ECONOMIC DAMAGE OR
INJURY TO PROPERTY AND LOST PROFITS, REGARDLESS OF WHETHER LICENSEE SHALL BE
ADVISED, SHALL HAVE OTHER REASONS TO KNOW, OR IN FACT SHALL KNOW OF THE
POSSIBILITY.

----------
* The information omitted is confidential and has been filed separately with the
  commission pursuant to Rule 406 of the Securities Act of 1933, as amended.

                                       11
<PAGE>

                          ARTICLE 9 - EXPORT CONTROLS

       It is understood that LICENSOR is subject to United States laws and
regulations controlling the export of technical data, computer software,
laboratory prototypes and other commodities (including the Arms Export Control
Act, as amended and the Export Administration Act of 1979), and that its
obligations hereunder are contingent on compliance with applicable United States
export laws and regulations. The transfer of certain technical data and
commodities may require a license from the cognizant agency of the United States
Government and/or written assurances by LICENSEE and LICENSEE shall not export
data of commodities to certain foreign countries without prior approval of such
agency. LICENSOR neither represents that a license shall not be required nor
that, if required, it shall be issued.

                         ARTICLE 10 - NON-USE OF NAMES

       LICENSEE shall not use the names or trademarks of the Texas Tech
University, nor any adaptation thereof, nor the names of any of its employees,
in any advertising, promotional or sales literature without prior written
consent obtained from LICENSOR, or said employee, in each case, except that
LICENSEE may state that it is licensed by LICENSOR under one or more of the
patents and/or applications comprising the PATENT RIGHTS.

                            ARTICLE 11 - ASSIGNMENT

       This Agreement is not assignable and any attempt to do so shall be void,
unless permitted in writing by LICENSOR, which permission will be unreasonably
withheld provided the economic interests of LICENSOR are protected.

                        ARTICLE 12 - DISPUTE RESOLUTION

       12.1   Except for the right of either party to apply to a court of
competent jurisdiction for a temporary restraining order, a preliminary
injunction, or other equitable relief to preserve the status quo or prevent
irreparable harm, any and all claims, disputes or controversies arising under,
out of, or in connection with the Agreement, including any dispute relating to
patent validity or infringement, which the parties shall be unable to resolve
within sixty (60) days shall be mediated in good faith. The party raising such
dispute shall promptly advise the other party of such claim, dispute or
controversy in a writing which describes in rea-

                                       12
<PAGE>

sonable detail the nature of such dispute. By not later than five (5) business
days after the recipient has received such notice of dispute, each party shall
have selected for itself a representative who shall have the authority to bind
such party, and shall additionally have advised the other party in writing of
the name and title of such representative. By not later than ten (10) business
days after the date of such notice of dispute, the party against whom the
dispute shall be raised shall select a mediation firm in the - area and such
representatives shall schedule a date with such firm for a mediation hearing.
The parties shall enter into good faith mediation and shall share the costs
equally. If the representatives of the parties have not been able to resolve the
dispute within fifteen (15) business days after such mediation hearing, the
parties shall have the right to pursue any other remedies legally available to
resolve such dispute in either the Courts of the State of Texas or in the United
States District Court for the District of Texas, to whose jurisdiction for such
purposes LICENSOR and LICENSEE each hereby irrevocably consents and submits.

       12.2   Notwithstanding the foregoing, nothing in this Article shall be
construed to waive any rights or timely performance of any obligations existing
under this Agreement.

                            ARTICLE 13 - TERMINATION

       13.1   If LICENSEE shall cease to carry on its business, this Agreement
shall terminate upon notice by LICENSOR.

       13.2   Should LICENSEE fail to make any payment whatsoever due and
payable to LICENSOR hereunder, LICENSOR shall have the right to terminate this
Agreement effective on ninety (90) days' notice, unless LICENSEE shall make all
such payments to LICENSOR within said ninety (90) day period. Upon the
expiration of the ninety (90) days period, if LICENSEE shall not have made all
such payments to LICENSOR, the rights, privileges and license granted hereunder
shall automatically terminate.

       13.3   Upon any material breach or default of this Agreement by LICENSEE
(including, but not limited to, breach or default under Paragraph 3.1), other
than those occurrences set out in Paragraphs 12.1 hereinabove, which shall
always take precedence in that order over any material breach or default
referred to in this Paragraph 12.1, LICENSOR shall have the right to terminate
this Agreement and the rights, privileges and license granted hereunder
effective in ninety (90) days' notice to LICENSEE. Such termination shall become
automatically effective unless LICENSEE shall have cured any such material
breach or default prior to the expiration of the ninety (90) day period.

                                       13
<PAGE>

       13.4   LICENSEE shall have the right to terminate this Agreement at any
time on a ninety (90) days notice to LICENSOR, and upon payment of all amounts
due LICENSOR through the effective date of the termination.

       13.5   Upon termination of this Agreement for any reason, nothing herein
shall be construed to release either party from any obligation that matured
prior to the effective date of such termination; and Articles 1, 7, 8, 9, 12.1.
No such articles shall survive any such termination. LICENSEE and any
sublicensee thereof may, however, after the effective date of such termination,
sell all LICENSED PRODUCTS, and complete LICENSED PRODUCTS in the process of
manufacture at the time of such termination and sell the same, provided that
LICENSEE shall make the payments to LICENSOR as required by Article 4 of this
Agreement and shall submit the reports required by Article 6 hereof.

       13.6   The termination of this Agreement for any reason shall not affect
the validity of the sublicenses then in effect, in accordance with and subject
to their terms; provided however, that such sublicenses shall at all times
remain subject to the terms hereof.

       13.7   This Agreement shall constitute the entire agreement of the
parties on the subject matter hereof superceding any prior oral or written
representations or agreements. No amendment or modification hereof shall be
valid or binding upon the parties unless made in writing and signed as
aforesaid.

                         ARTICLE 14 - PAYMENTS, NOTICES
                            AND OTHER COMMUNICATIONS

       Any payment, notice or other communication pursuant to this Agreement
shall be sufficiently made or given on the date of mailing if sent to such party
by certified first class mail, postage prepaid, addressed to it at its address
below or as it shall designate by written notice given to the other party:

       In the case of LICENSOR:

                                   Director
                                   Technology Transfer and Intellectual Property
                                   Box 42007
                                   Texas Tech University Systems
                                   Lubbock, TX 79409-2007

                                       14
<PAGE>

In the case of LICENSEE:           CEO
                                   HemoBioTech, Inc.
                                   Suite 2006
                                   15889 Preston Road
                                   Dallas, Texas 75248

                     ARTICLE 15 - MISCELLANEOUS PROVISIONS

       15.1   This Agreement shall be construed, governed, interpreted and
applied in accordance with the laws of the State of Texas, U.S.A., except that
questions affecting the construction and effect of any patent shall be
determined by the law of the country in which the patent was granted.

       15.2   The parties hereto acknowledge that this Agreement sets forth the
entire Agreement and understanding of the parties hereto as to the subject
matter hereof, and shall not be subject to any change or modification except by
the execution of a written instrument subscribed to by the parties hereto.

       15.3   The provisions of this Agreement are severable, and in the event
that any provisions of this Agreement shall be determined to be invalid or
unenforceable under any controlling body of the law, such invalidity or
unenforceability shall not in any way affect the validity or enforceability of
the remaining provisions hereof.

       15.4   LICENSEE agrees to make the LICENSED PRODUCTS sold in the United
States with all applicable United States patent numbers. All LICENSED PRODUCTS
shipped to or sold in other countries shall be marked in such a manner as to
conform with the patent laws and practice of the country of manufacture or sale.

       15.5   The failure of either party to assert a right hereunder or to
insist upon compliance with any term or condition o this Agreement shall not
constitute a waiver of that right or excuse a similar subsequent failure to
perform any such term or condition by the other party.

                                       15
<PAGE>

       IN WITNESS WHEREOF, the parties have duly executed this Agreement the day
and year set forth below.

Texas Tech University Systems

By /s/ H. Walter Haeussler
  ---------------------------------
Name   H. Walter Haeussler
       ----------------------------
Title  Dir. Tech. Transfer & I.P.
       ----------------------------
Date   Feb. 12, 2002
       ----------------------------

HemoBioTech, Inc.

By /s/ Ghassan Nino
  ---------------------------------
Name:  Ghassan Nino
       ----------------------------
Title: Interim President
       ----------------------------
Date:  January 27, 2002
       ----------------------------

                                       16
<PAGE>

                                   APPENDIX A
                                   ----------

UNITED STATES PATENT RIGHTS

LICENSOR Case No. TTU D-0177

U.S. Patent No. 5,439,882
Issued 8-8-95

                                       17
<PAGE>

                                   APPENDIX B
                                   ----------

1.     FOREIGN PATENT APPLICATIONS AND PATENTS WITHIN THE PATENT RIGHTS AS OF
       EFFECTIVE DATE:

       For LICENSOR Case No. D-0177:

Australia                  650439
                           565763

Austria                    0507870

Belgium                    0507870

Canada                     2,103,680
                           2,072,081

Denmark                    0507870

Europe                     0586381

Finland                    922937
                           933550
                           106362

France                     0507870
                           0586381

Germany                    0507870
                           0586381

Great Britain              0507870

Greece                     3019775

Ireland                    73248

Italy                      0507870

Japan                      2954347

                                       18
<PAGE>

Korea                      168866
                           227453

Luxembourg                 0507870
                           0586381

Netherlands                0507870

Norway                     19922551=309799
                           308934
                           932857

Portugal                   96398 (dropped)

Spain                      91902885.2

Sweden                     91902885.2

Switzerland                0507870

                                       19

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00082-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00082-of-00352.parquet"}]]